Clinical evaluation of FMT is progressing without an adequate understanding of the underlying ecological dynamics; studies are now beginning to fill these gaps, but consensus will be needed on many fronts.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Promiscuous, persistent and problematic: insights into current enterococcal genomics to guide therapeutic strategy
BMC Microbiology Open Access 28 March 2024
-
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Nature Medicine Open Access 16 February 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
van Nood, E. et al. N. Engl. J. Med. 368, 407–415 (2013).
Mullish, B. H. et al. J. Hosp. Infect. 100, S1–S31 (2018).
Costello, S. P. et al. Gastroenterology 152, S198–S199 (2017).
Goll, R. et al. Gut Microbes 12, 1794263 (2020).
Vrieze, A. et al. Gastroenterology 143, 913–916.e7 (2012).
Baruch, E. N. et al. Science 371, 602–609 (2021).
Ianiro, G. Nat. Med. et al. https://doi.org/10.1038/s41591-022-01964-3 (2022).
Schmidt, T. S. B. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01913-0 (2022).
Sokol, H. et al. Microbiome 8, 12 (2020).
Kong, L. et al. Gastroenterology 159, 2193–2202.e5 (2020).
Li, S. S. et al. Science 352, 586–589 (2016).
Danne, C., Rolhion, N. & Sokol, H. Nat. Rev. Gastroenterol. Hepatol. 18, 503–513 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.S. reports lecture fee, board membership or consultancy from Carenity, AbbVie, Astellas, Amgen Servier, Danone, Ferring, Mayoly Spindler, MSD, Novartis, Roche, Tillots, BiomX, Biose, Novartis,Takeda, Fresenius, Adaren Nestle, Sanofi and Biocodex, possessed stocks from Enterome and is co-founder of Exeliom Biosciences.
Rights and permissions
About this article
Cite this article
Lavelle, A., Sokol, H. Understanding and predicting the efficacy of FMT. Nat Med 28, 1759–1760 (2022). https://doi.org/10.1038/s41591-022-01991-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01991-0
This article is cited by
-
Promiscuous, persistent and problematic: insights into current enterococcal genomics to guide therapeutic strategy
BMC Microbiology (2024)
-
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Nature Medicine (2024)
-
Utilization of the microbiome in personalized medicine
Nature Reviews Microbiology (2023)